Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2009-2-10
pubmed:abstractText
CD4(+)CD25(+)FOXP3(+) regulatory T cells (Treg) successfully control graft-versus-host-disease (GVHD) in animal models. In humans, incomplete reconstitution of Treg after allogeneic hematopoietic stem cell transplantation (HSCT) has been associated with chronic GVHD (cGVHD). Recent studies have demonstrated that interleukin (IL)-2 infusions expand Treg in vivo. However, the effectiveness of this therapy depends on the number of cells capable of responding to IL-2. We examined the effect of low-dose IL-2 infusions on Treg populations after HSCT in patients who also received infusions of donor CD4(+) lymphocytes. Utilizing FOXP3 as a Treg marker, we found that patients who received CD4+DLI concomitantly with IL-2 had greater expansion of Treg compared to patients who received IL-2 (P = .03) or CD4(+)DLI alone (P = .001). FOXP3 expression correlated with absolute CD4(+)CD25(+) cell counts. Moreover, expanded CD4(+)CD25(+) T cells displayed normal suppressive function and treatment with CD4(+)DLI and IL-2 was not associated with GVHD. This study suggests that administration of low-dose IL-2 combined with adoptive CD4(+) cellular therapy may provide a mechanism to expand Treg in vivo.
pubmed:grant
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/19203731-12114403, http://linkedlifedata.com/resource/pubmed/commentcorrection/19203731-12163568, http://linkedlifedata.com/resource/pubmed/commentcorrection/19203731-12463482, http://linkedlifedata.com/resource/pubmed/commentcorrection/19203731-12720217, http://linkedlifedata.com/resource/pubmed/commentcorrection/19203731-12925844, http://linkedlifedata.com/resource/pubmed/commentcorrection/19203731-14660744, http://linkedlifedata.com/resource/pubmed/commentcorrection/19203731-15031211, http://linkedlifedata.com/resource/pubmed/commentcorrection/19203731-15090447, http://linkedlifedata.com/resource/pubmed/commentcorrection/19203731-15172973, http://linkedlifedata.com/resource/pubmed/commentcorrection/19203731-15327522, http://linkedlifedata.com/resource/pubmed/commentcorrection/19203731-15972448, http://linkedlifedata.com/resource/pubmed/commentcorrection/19203731-1607923, http://linkedlifedata.com/resource/pubmed/commentcorrection/19203731-16278306, http://linkedlifedata.com/resource/pubmed/commentcorrection/19203731-16304057, http://linkedlifedata.com/resource/pubmed/commentcorrection/19203731-16376102, http://linkedlifedata.com/resource/pubmed/commentcorrection/19203731-16399597, http://linkedlifedata.com/resource/pubmed/commentcorrection/19203731-16412790, http://linkedlifedata.com/resource/pubmed/commentcorrection/19203731-16431128, http://linkedlifedata.com/resource/pubmed/commentcorrection/19203731-16503495, http://linkedlifedata.com/resource/pubmed/commentcorrection/19203731-16645171, http://linkedlifedata.com/resource/pubmed/commentcorrection/19203731-16699377, http://linkedlifedata.com/resource/pubmed/commentcorrection/19203731-1730094, http://linkedlifedata.com/resource/pubmed/commentcorrection/19203731-8043878, http://linkedlifedata.com/resource/pubmed/commentcorrection/19203731-9108425, http://linkedlifedata.com/resource/pubmed/commentcorrection/19203731-9573003
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
1523-6536
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
15
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
382-8
pubmed:dateRevised
2010-9-22
pubmed:meshHeading
pubmed:year
2009
pubmed:articleTitle
Combined CD4+ donor lymphocyte infusion and low-dose recombinant IL-2 expand FOXP3+ regulatory T cells following allogeneic hematopoietic stem cell transplantation.
pubmed:affiliation
Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural